Donislecel

Analysis of the online conversation among health care professionals on social media in July revealed significant online discussion and support for the first-ever nonprescription daily oral contraceptive, norgestrel 0.075 mg.

For people living with type 1 diabetes and the clinicians and researchers who treat and study the disease, 2021 was a year of groundbreaking achievements and cause for optimism. Though as with any new experimental treatments, caveats abound.

On April 15, an FDA advisory committee concluded that the islet cell therapy donislecel demonstrated a favorable risk-benefit profile for certain patients with difficult-to-control type 1 diabetes.

An FDA advisory committee concluded that the investigational cell therapy donislecel demonstrated a favorable risk-benefit profile for certain patients with difficult-to-control type 1 diabetes.